202 related articles for article (PubMed ID: 29412183)
1. Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: An ACTTION Systematic Review.
Gewandter JS; Chaudari J; Iwan KB; Kitt R; As-Sanie S; Bachmann G; Clemens Q; Lai HH; Tu F; Verne GN; Vincent K; Wesselmann U; Zhou Q; Turk DC; Dworkin RH; Smith SM
J Pain; 2018 Jul; 19(7):717-726. PubMed ID: 29412183
[TBL] [Abstract][Full Text] [Related]
2. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome.
Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760
[TBL] [Abstract][Full Text] [Related]
3. The role of glycosaminoglycans in the management of chronic pelvic pain: a systematic review.
Iacovelli V; Bianchi D; Pletto S; Pacini P; Fede Spicchiale C; Finazzi Agrò E
Minerva Urol Nefrol; 2020 Jun; 72(3):321-331. PubMed ID: 32182229
[
